对原发性肿瘤进行放疗：转移性前列腺癌个体化治疗的第一步。
Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer.
作者信息
Ferro Matteo, Crocetto Felice, Lucarelli Giuseppe, Lievore Elena, Barone Biagio
机构信息
Department of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, Italy.
Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80131 Naples, Italy.
出版信息
Diagnostics (Basel). 2022 Aug 16;12(8):1981. doi: 10.3390/diagnostics12081981.
Abstract
Prostate cancer is the first most frequent cancer in men worldwide, with over 250,000 estimated new cases diagnosed in 2021 [...].
摘要
前列腺癌是全球男性中最常见的癌症，据估计2021年有超过25万例新病例被诊断出来[...]。
相似文献
1
Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer.对原发性肿瘤进行放疗：转移性前列腺癌个体化治疗的第一步。
Diagnostics (Basel). 2022 Aug 16;12(8):1981. doi: 10.3390/diagnostics12081981.
2
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".自动骨扫描指数作为预测新发转移性前列腺癌男性前列腺放射治疗反应的指标：STAMPEDE 的“M1|RT 比较”的探索性分析。
Eur Urol Oncol. 2020 Aug;3(4):412-419. doi: 10.1016/j.euo.2020.05.003. Epub 2020 Jun 24.
3
Prostate radiotherapy in newly diagnosed metastatic prostate cancer.初诊转移性前列腺癌的前列腺放射治疗。
Curr Opin Urol. 2019 Nov;29(6):620-628. doi: 10.1097/MOU.0000000000000675.
4
Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.晚期和转移性前列腺癌患者采用积极治疗与保守治疗的 9 年前列腺癌生存差异。
Cancer. 2018 May 1;124(9):1921-1928. doi: 10.1002/cncr.31285. Epub 2018 Mar 2.
5
Management and characteristics of patients with metastatic prostate cancer in a cohort of New Zealand men.一组新西兰男性中转移性前列腺癌患者的管理与特征
Oncology. 2015;88(3):157-63. doi: 10.1159/000368319. Epub 2014 Nov 15.
6
Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer.现代放疗与免疫疗法在转移性前列腺癌治疗中的相互作用
Front Oncol. 2021 Sep 14;11:744679. doi: 10.3389/fonc.2021.744679. eCollection 2021.
7
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?转移性前列腺癌原发灶的放射治疗：仅用于姑息治疗还是改变肿瘤生物学特性？
Curr Opin Urol. 2017 Nov;27(6):580-586. doi: 10.1097/MOU.0000000000000444.
8
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.病理分期晚期前列腺癌的辅助放疗：一项随机临床试验。
JAMA. 2006 Nov 15;296(19):2329-35. doi: 10.1001/jama.296.19.2329.
9
Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.新诊断寡转移前列腺癌中前列腺近距离放疗与转移灶定向放疗联合应用的长期结果：一项回顾性队列研究。
Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.
10
New developments in metastatic prostate cancer therapy.转移性前列腺癌治疗的新进展
Practitioner. 2015 Apr;259(1781):21-4, 2-3.
引用本文的文献
1
Focal boosted IMRT treatment of prostate cancer to 84 Gy in 28 fractions: preliminary clinical outcomes, toxicity, and dosimetry.前列腺癌的局部增强调强放射治疗，28次分割达84 Gy：初步临床结果、毒性及剂量学
Front Oncol. 2025 May 20;15:1577359. doi: 10.3389/fonc.2025.1577359. eCollection 2025.
2
Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada.转移性去势敏感性前列腺癌的治疗强化：加拿大艾伯塔省的一项真实世界研究。
Future Oncol. 2025 Apr;21(10):1197-1207. doi: 10.1080/14796694.2025.2479374. Epub 2025 Mar 24.
3
Real-World Treatment Patterns and Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights From a Retrospective Cohort Study.转移性激素敏感性前列腺癌的真实世界治疗模式与生存结局：一项回顾性队列研究的见解
Cancer Manag Res. 2025 Mar 1;17:419-428. doi: 10.2147/CMAR.S506423. eCollection 2025.
4
Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.突破现状：当疾病负荷和转移时间不足以实现mHSPC治疗个体化时。
Future Oncol. 2025 Apr;21(8):991-1003. doi: 10.1080/14796694.2025.2468569. Epub 2025 Mar 3.
5
Natural Compounds and Histone Deacetylase Inhibitors: A Combined Approach Against mCRPC Cells.天然化合物与组蛋白去乙酰化酶抑制剂：一种针对去势抵抗性前列腺癌细胞的联合方法
Biomedicines. 2025 Jan 25;13(2):296. doi: 10.3390/biomedicines13020296.
6
An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer.一种用于预测转移性去势抵抗性前列腺癌患者接受阿比特龙治疗后前列腺特异性抗原反应的MRI影像组学模型。
Front Oncol. 2025 Jan 27;15:1491848. doi: 10.3389/fonc.2025.1491848. eCollection 2025.
7
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial.新辅助激素治疗高危前列腺癌后的肿瘤消退：一项随机 II 期试验的病理结果。
World J Urol. 2024 Nov 2;42(1):618. doi: 10.1007/s00345-024-05323-4.
8
Lower baseline testosterone level is related to earlier development of castration resistance in metastatic prostate cancer: a multi-center cohort study.较低的基线睾酮水平与转移性前列腺癌去势抵抗的早期发生相关：一项多中心队列研究。
Front Oncol. 2024 Feb 20;14:1321522. doi: 10.3389/fonc.2024.1321522. eCollection 2024.
9
Influence of the Hypersensitivity to Low Dose Phenomenon on the Tumor Response to Hypofractionated Stereotactic Body Radiation Therapy.低剂量现象超敏反应对肿瘤在立体定向体部放射治疗中低分次照射反应的影响。
Cancers (Basel). 2023 Aug 5;15(15):3979. doi: 10.3390/cancers15153979.
10
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases.曲妥珠单抗联合放疗和抗 HER2 靶向治疗 HER2 阳性乳腺癌脑转移
Eur J Med Res. 2023 Jan 16;28(1):27. doi: 10.1186/s40001-022-00894-7.
本文引用的文献
1
Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.多西他赛联合雄激素受体轴靶向治疗和雄激素剥夺治疗在转移性激素敏感前列腺癌中的应用：一项网状荟萃分析。
Eur Urol Oncol. 2022 Oct;5(5):494-502. doi: 10.1016/j.euo.2022.06.003. Epub 2022 Jul 8.
2
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌（PEACE-1）：一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
3
Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization.前列腺癌放射组学——从成像到分子特征分析。
Int J Mol Sci. 2021 Sep 15;22(18):9971. doi: 10.3390/ijms22189971.
4
Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.联合骨闪烁扫描和氟胆碱正电子发射断层扫描/计算机断层扫描可预测前列腺癌患者对镭-223治疗的反应。
Future Sci OA. 2021 May 21;7(8):FSO719. doi: 10.2144/fsoa-2021-0053. eCollection 2021 Sep.
5
Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer.PSMA正电子发射断层扫描引导下的放射治疗对寡转移去势抵抗性前列腺癌的疗效
Front Oncol. 2021 Apr 19;11:664225. doi: 10.3389/fonc.2021.664225. eCollection 2021.
6
Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer.新诊断的转移性前列腺癌的前列腺放疗长期疗效
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1041-1047. doi: 10.1038/s41391-021-00339-y. Epub 2021 Apr 5.
7
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
8
Whole-body magnetic resonance imaging for prostate cancer assessment: Current status and future directions.用于前列腺癌评估的全身磁共振成像：现状与未来方向。
J Magn Reson Imaging. 2022 Mar;55(3):653-680. doi: 10.1002/jmri.27485. Epub 2020 Dec 31.
9
Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review.转移性激素敏感性前列腺癌的联合放疗、全身治疗及雄激素剥夺治疗的比较疗效：一项网状Meta分析和系统评价
Front Oncol. 2020 Oct 20;10:567616. doi: 10.3389/fonc.2020.567616. eCollection 2020.
10
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌诊治指南。第二部分-2020 年更新：复发性和转移性前列腺癌的治疗。
Eur Urol. 2021 Feb;79(2):263-282. doi: 10.1016/j.eururo.2020.09.046. Epub 2020 Oct 7.
Zotero 插件